A sirolimus-eluting iron bioresorbable scaffold was noninferior to conventional stents for preventing arterial narrowing after angioplasty at 2 years , though higher rates of repeat interventions warrant monitoring in longer-term follow-up.
IRONMAN-II tested a newer approach to opening blocked coronary arteries. Rather than using permanent metal stents (the current standard), researchers compared a temporary iron scaffold that dissolves over time against traditional everolimus-eluting stents in 518 patients with coronary artery disease. The iron scaffolds were thinner and designed to provide structural support during vessel healing before being absorbed by the body. If proven superior, this approach could theoretically restore normal vessel function after the scaffold disappears, whereas permanent stents remain in place indefinitely.
The key finding: iron scaffolds performed similarly to conventional stents at preventing restenosis (renarrowing of the vessel). At 2 years, late lumen loss—the standard measure of how much the artery narrows after intervention—was 0.28 mm with iron scaffolds versus 0.23 mm with conventional stents. The difference of 0.05 mm exceeded the noninferiority margin of 0.08 mm, meeting the trial's primary endpoint. Blood flow measurements using quantitative flow reserve (QFR) and optical coherence tomography also showed comparable results between groups, suggesting the scaffolds supported adequate circulation during the critical healing window.
However, the data revealed important caveats. Patients receiving iron scaffolds experienced higher rates of binary restenosis (16.2% vs 10.9%) and repeat interventions compared to those with conventional stents. Target lesion failure—a composite measure including death, heart attack, or repeat revascularization—occurred in 7.4% of scaffold patients versus 5.4% of stent patients, though this 37% relative increase was not statistically significant given the small number of events. Notably, most repeat interventions in the scaffold group were triggered by findings on angiography without evidence of inadequate blood flow, suggesting some were potentially unnecessary. No scaffold thrombosis (clotting) occurred in the iron group, whereas one stent thrombosis was documented in the conventional group, though both represent very low absolute rates.
The critical unanswered question is what happens after the iron scaffold completely dissolves, typically 12-24 months post-procedure. This 2-year trial captured the period of resorption but not the long-term consequences. The authors explicitly state that "longer-term follow-up is necessary to demonstrate whether late benefits are realized after complete IBS resorption." The scaffold's advantage would theoretically emerge only if late-term clinical outcomes improve after vessel remodeling completes, but the trial provides no evidence for this benefit yet.
If you're considering percutaneous coronary intervention for coronary artery disease, this research confirms that bioresorbable scaffolds are a viable alternative to conventional stents from a safety perspective. However, you should be aware that current evidence doesn't demonstrate they're clearly superior. The iron scaffold approach appears to work as well in the short term (2 years), but the higher rate of repeat angiographic abnormalities and interventions suggests you may face additional procedures. The real question—whether dissolving scaffolds offer advantages years after the procedure—remains unanswered and will require tracking patients beyond 5 years.
This is an area where longer-term data matters significantly. If you have the option to enroll in extended follow-up studies tracking these patients, that information will clarify whether the theoretical benefits of bioresorbable scaffolds materialize.
| Characteristic | Details |
|---|---|
| Study type | Prospective, multicenter, single-blinded, randomized noninferiority trial |
| Sample size | 518 participants (259 iron scaffolds, 259 conventional stents) |
| Study duration | 2 years of follow-up; patients enrolled March-December 2022 |
| Interventions | Sirolimus-eluting iron bioresorbable scaffold vs. cobalt chromium everolimus-eluting stents |
| Primary outcome | 2-year in-segment late lumen loss |
| Key secondary outcomes | Quantitative flow reserve, OCT-derived flow area, target lesion failure, patient-oriented composite endpoint |
| Locations | 36 centers in China |
| Clinicaltrials.gov | NCT05206084 |
Gao X, et al. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). J Am Coll Cardiol. 2024. PubMed: 41670556
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.